Head-to-head evidence
BCD-281 vs Ofatumumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
BCD-281
Developed by Biocad
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07321093 (registry estimate)
Ofatumumab
Marketed by Novartis and partners
NCT02792231 · Phase 3 · completed
This was a large, randomized, quadruple-blind, active-controlled trial of 955 participants, comparing ofatumumab with teriflunomide. The prespecified primary clinical endpoint, annualized confirmed relapse rate, was significantly better with ofatumumab (p<0.001), supporting a strong evidence grade despite mixed findings for some secondary measures.
Next expected readout: April 2027 · NCT05090371 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-281's landscape · Ofatumumab's landscape